Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the launch ...

Protein variant characterization remains a central challenge in precision oncology, where understanding the functional consequences of sequence alterations can inform and drive therapeutic development ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ™, today announced a new paper that was submitted to ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule ...

Due to its high accuracy and fast, simple workflow, capillary electrophoresis (CE) is a foundational technology for clinical applications. CE is an invaluable tool used to detect genetic variations ...

BRANFORD, Conn., September 08, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through ...

ProteoVue is part of broader set of innovation initiatives, including the Company’s recently announced collaboration with NVIDIA, to leverage AI to enhance sequencing performance BRANFORD, Conn., ...

Due to its high accuracy and fast, simple workflow, capillary electrophoresis (CE) is a foundational technology for clinical applications. CE is an invaluable tool used to detect genetic variations ...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the launch ...

BRANFORD, Conn. - Quantum-Si Incorporated (NASDAQ:QSI), a $377 million market cap biotechnology company known as The Protein Sequencing Company™, has announced the release of its latest benchtop ...